ArticleAnnals of clinical and translational neurology2021
Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease.
Article in Annals of clinical and translational neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.Brain : a journal of neurology · 2021Trial
- Plasma proteomic signatures of preclinical Alzheimer's disease biomarkers and memory in clinically unimpaired older adults.medRxiv : the preprint server for health sciences · 2025Article
- Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging.Alzheimer's research & therapy · 2025Article
- The relationships between cerebrospinal fluid neurofilament light chain and hippocampal atrophy with cognitive decline.Journal of Alzheimer's disease : JAD · 2025Article
- The association between plasma and MRI biomarkers in dementia with lewy bodies.Alzheimer's research & therapy · 2025Article
- Associations of plasma biomarkers with cerebral perfusion and structure in Alzheimer's disease.Translational psychiatry · 2025Article
- Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP) cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Plasma levels of phosphorylated tau and neurofilament light chain as potential biomarkers for Alzheimer's disease: A biochemical analysis in Pakistani population.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023Article
- Predicting progression to Alzheimer's disease with human hippocampal progenitors exposed to serum.Brain : a journal of neurology · 2023Article
- Blood biomarkers for Alzheimer's disease in clinical practice and trials.Nature aging · 2023Review
- Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.JAMA network open · 2023Article
- Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.International journal of molecular sciences · 2023Article
- Article
- Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.CNS neuroscience & therapeutics · 2022Article
- Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease.Biomedicines · 2022Article
- Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.Alzheimer's research & therapy · 2022Review
- Self- and Partner-Reported Subjective Memory Complaints: Association with Objective Cognitive Impairment and Risk of Decline.Journal of Alzheimer's disease reports · 2022Article
- Association of plasma P-tau181 with memory decline in non-demented adults.Brain communications · 2021Article
- Identification of plasma proteins relating to brain neurodegeneration and vascular pathology in cognitively normal individuals.Alzheimer's & dementia (Amsterdam, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
We examined if plasma phosphorylated tau is associated with neurodegeneration in Alzheimer's disease. We investigated 372 cognitively unimpaired participants, 554 mild cognitive impairment patients, and 141 Alzheimer's disease dementia patients. Tau phosphorylated at threonine 181, regional cortical thickness (using magnetic resonance imaging) and hypometabolism (using fluorodeoxyglucose positron emission tomography) were measured longitudinally. High plasma tau was associated with hypometabolism and cortical atrophy at baseline and over time, and longitudinally increased tau was associated with accelerated atrophy, but these associations were only observed in Aβ-positive participants. Plasma phosphorylated tau may identify and track processes linked to neurodegeneration in Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.